Tokarski, John S <br/><br/>
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.  [electronic resource] 

 -  Cancer research  Jun 2006 
 - 5790-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-05-4187  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Benzamides<br/>Crystallography, X-Ray<br/>Dasatinib<br/>Drug Resistance, Neoplasm<br/>Enzyme Activation<br/>Humans<br/>Imatinib Mesylate<br/>Models, Molecular<br/>Piperazines--chemistry<br/>Protein Conformation<br/>Protein Kinase Inhibitors--chemistry<br/>Protein Structure, Tertiary<br/>Proto-Oncogene Proteins c-abl--antagonists & inhibitors<br/>Pyrimidines--chemistry<br/>Structure-Activity Relationship<br/>Thiazoles--chemistry